Faecalibacterium Prausnitzii Test

Faecalibacterium prausnitzii (F. prausnitzii) is one of the most abundant bacteria in a healthy adult colon and is considered a keystone species because of the unique metabolic and immune functions it performs. It is an anaerobic bacterium, meaning it survives and grows only in environments without oxygen. Its most important contribution to health is its ability to produce butyrate, a short chain fatty acid created when gut bacteria ferment dietary fiber. Butyrate serves as the main energy source for colon cells, strengthens the gut barrier, and regulates inflammation through several immune pathways. A strong gut barrier prevents unwanted molecules and microbes from crossing into the bloodstream, a process sometimes referred to as intestinal permeability or “leaky gut”.

Beyond butyrate, F. prausnitzii produces additional anti-inflammatory molecules, including a protein called MAM. This protein reduces the activity of inflammatory cytokines, which are signaling proteins the immune system uses to coordinate inflammation. At the same time, F. prausnitzii promotes regulatory T cells, often called Tregs, which help maintain immune tolerance and prevent overactive immune responses. This combination of butyrate production, cytokine modulation, and Treg stimulation gives F. prausnitzii a unique role in calming inflammation locally in the gut and systemically throughout the body.

Low levels of F. prausnitzii are consistently observed in inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis. In these conditions, reduced butyrate production weakens the gut barrier and allows higher levels of inflammatory signaling. Experimental models show that restoring F. prausnitzii or increasing its fermentation products improves gut barrier integrity, reduces inflammatory cytokines, and eases clinical symptoms. Sleep deprivation, chronic stress, and Western-style diets low in fermentable fiber can also reduce its abundance.

Low F. prausnitzii is not limited to gut disease. Multiple studies link its depletion with metabolic disorders such as type 2 diabetes, autoimmune conditions, chronic fatigue syndrome, and some cancers. In metabolic disease, lower butyrate availability may impair glucose regulation and increase systemic inflammation. In cancer and cancer immunotherapy, F. prausnitzii has been associated with improved treatment responses and reduced treatment-related colitis, possibly through its effects on immune balance and the gut barrier.

Dietary habits are one of the strongest determinants of F. prausnitzii abundance. Diets rich in fermentable fibers such as resistant starch, oats, legumes, and many vegetables provide the substrates this bacterium needs to produce butyrate. Certain probiotic approaches and targeted microbiome therapies are being explored, although maintaining oxygen-free conditions makes direct supplementation challenging. That said, strategies that increase the overall capacity of the gut microbiome to produce butyrate often increase F. prausnitzii as part of a larger beneficial ecosystem shift.